GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically meaningful types of bacteria.
The companyâ€™s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).
GangaGen, Inc. was founded in India in 2000 and incorporated in the US in 2001 by Dr. J. Ramachandran, with the aim to develop novel therapies for treating antibiotic-resistant infection.
The company is led by a senior research team with extensive drug discovery expertise. GangaGen develops anti-microbial products to control multiple species of bacteria pathogenic to humans.
GangaGen is pursuing specific human applications which pose a serious public health threat, such as antibiotic-resistant strains.